A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
NCT06126575
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
Elacestrant dihydrochloride
Sponsor
Stemline Therapeutics, Inc.